🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Hybio Pharmaceutical Co., Ltd. (SHE:300199)
China flag China · Delayed Price · Currency is CNY
19.59
-1.47 (-6.98%)
Nov 20, 2026, 3:04 PM CST

Hybio Pharmaceutical Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Operating Revenue
1,487927.73547.2383.13692.29730.93
Other Revenue
38.6338.634348.2512.035.04
1,526966.35590.2431.38704.32735.97
Revenue Growth
69.87%63.73%36.81%-38.75%-4.30%1.97%
Cost of Revenue
590.06427.23281.47260.42194.83271.88
Gross Profit
935.54539.12308.73170.97509.49464.1
Selling, General & Admin
201.54226.55240.13367.6484.36545.43
Research & Development
212125.1987.33159.6154.79101.94
Other Operating Expenses
34.9711.958.1312.2216.5216.78
Operating Expenses
464.14370.78341.14542.38691.62734.37
Operating Income
471.4168.34-32.41-371.41-182.13-270.27
Interest Expense
-85.75-98.04-106.5-120.46-103.25-87.92
Interest & Investment Income
48.291.911.90.220.57391.46
Currency Exchange Gain (Loss)
0.840.843.640.291.64-1.55
Other Non Operating Income (Expenses)
-12.57-16.6-10.45-11.2-10.01-16.22
EBT Excluding Unusual Items
422.2156.46-143.82-502.57-293.1815.48
Gain (Loss) on Sale of Investments
-0.130.15-34.71-89.77-16.47
Gain (Loss) on Sale of Assets
0.960.6442.78-0.513.4135.2
Asset Writedown
-13.1-12.47-82.43-90.81-17.51-41.99
Legal Settlements
------1.24
Other Unusual Items
27.9319.4521.0648.0824.2442.71
Pretax Income
437.8764.23-162.41-511.1-372.8133.68
Income Tax Expense
38.4230.217.684.34-0.275.24
Earnings From Continuing Operations
399.4534.03-180.09-515.44-372.5528.44
Minority Interest in Earnings
2.412.546.441.5722.37
Net Income
401.8636.57-173.65-513.88-370.5530.81
Net Income to Common
401.8636.57-173.65-513.88-370.5530.81
Net Income Growth
------
Shares Outstanding (Basic)
9149148688868821,027
Shares Outstanding (Diluted)
9149148688868821,027
Shares Change
3.29%5.29%-2.00%0.42%-14.09%11.21%
EPS (Basic)
0.440.04-0.20-0.58-0.420.03
EPS (Diluted)
0.440.04-0.20-0.58-0.420.03
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
14.76-0.4548.87-85.3-174.04-42.17
Free Cash Flow Per Share
0.02-0.06-0.10-0.20-0.04
Gross Margin
61.32%55.79%52.31%39.63%72.34%63.06%
Operating Margin
30.90%17.42%-5.49%-86.10%-25.86%-36.72%
Profit Margin
26.34%3.78%-29.42%-119.12%-52.61%4.19%
Free Cash Flow Margin
0.97%-0.05%8.28%-19.77%-24.71%-5.73%
EBITDA
588.94298.7115.03-222.64-52.6-144.93
EBITDA Margin
38.60%30.91%19.49%-51.61%-7.47%-19.69%
D&A For EBITDA
117.54130.36147.44148.77129.53125.35
EBIT
471.4168.34-32.41-371.41-182.13-270.27
EBIT Margin
30.90%17.42%-5.49%-86.10%-25.86%-36.72%
Effective Tax Rate
8.77%47.02%---15.57%
Revenue as Reported
1,526966.35590.2431.38704.32735.97